Pancreatic	O
islet	O
enhancer	O
clusters	O
enriched	O
in	O
type	B-DISEASE
2	I-DISEASE
diabetes	E-DISEASE
risk	O
-	O
associated	O
variants	O
.	O
Type	B-DISEASE
2	I-DISEASE
diabetes	E-DISEASE
affects	O
over	O
300	O
million	O
people	O
,	O
causing	O
severe	O
complications	O
and	O
premature	O
death	O
,	O
yet	O
the	O
underlying	O
molecular	O
mechanisms	O
are	O
largely	O
unknown	O
.	O
Pancreatic	B-DISEASE
islet	I-DISEASE
dysfunction	E-DISEASE
is	O
central	O
in	O
type	B-DISEASE
2	I-DISEASE
diabetes	E-DISEASE
pathogenesis	O
,	O
and	O
understanding	O
islet	O
genome	O
regulation	O
could	O
therefore	O
provide	O
valuable	O
mechanistic	O
insights	O
.	O


We	O
have	O
now	O
mapped	O
and	O
examined	O
the	O
function	O
of	O
human	O
islet	O
cis	O
-	O
regulatory	O
networks	O
.	O


We	O
identify	O
genomic	O
sequences	O
that	O
are	O
targeted	O
by	O
islet	O
transcription	O
factors	O
to	O
drive	O
islet	O
-	O
specific	O
gene	O
activity	O
and	O
show	O
that	O
most	O
such	O
sequences	O
reside	O
in	O
clusters	O
of	O
enhancers	O
that	O
form	O
physical	O
three	O
-	O
dimensional	O
chromatin	O
domains	O
.	O


We	O
find	O
that	O
sequence	O
variants	O
associated	O
with	O
type	B-DISEASE
2	I-DISEASE
diabetes	E-DISEASE
and	O
fasting	B-DISEASE
glycemia	E-DISEASE
are	O
enriched	O
in	O
these	O
clustered	O
islet	O
enhancers	O
and	O
identify	O
trait	O
-	O
associated	O
variants	O
that	O
disrupt	O
DNA	O
binding	O
and	O
islet	O
enhancer	O
activity	O
.	O


Our	O
studies	O
illustrate	O
how	O
islet	O
transcription	O
factors	O
interact	O
functionally	O
with	O
the	O
epigenome	O
and	O
provide	O
systematic	O
evidence	O
that	O
the	O
dysregulation	O
of	O
islet	O
enhancers	O
is	O
relevant	O
to	O
the	O
mechanisms	O
underlying	O
type	B-DISEASE
2	I-DISEASE
diabetes	E-DISEASE
.	O
